01 February 2006
Formation of rheumatoid pulmonary nodules during the leflunomide treatment
Štefan Alušík, Jan Fanta, Václav Eis, Václav Mandys, Jan PavlíčekCase Rep Clin Pract Rev 2006; 7:139-142 :: ID: 452142
Abstract
Background: Rheumatoid nodules develop mostly subcutaneously, they are less common in other organs.
Recent studies have described formation of rheumatoid nodules or growth acceleration of existing nodules in relation to the treatment. The development or growth acceleration of rheumatoid nodules is known to be related to the treatment with methotrexate, etanercept, infliximab and leflunomide.
Case Report: A 59-year-old female patient was treated 9 years for seropositive rheumatoid arthritis. She
took hydroxychloroquine, sulfasalazine, methotrexate and etanercept successively. Until then, the patient had suffered no rheumatoid nodules (not even subcutaneous). Isolated rheumatoid nodules were formed in her lungs when treated with leflunomide. The patient has been monitored after discontinuation of leflunomide treatment for the period of 20 months and only a mild progression of her lung disease has occurred.
Conclusions: Isolated rheumatoid nodules were formed in the lungs of our patient during leflunomide
treatment. In addition to methotrexate, etanercept and infliximab, leflunomide can probably also cause the formation and growth acceleration of rheumatoid nodules.
Keywords: rheumatoid arthritis, rheumatoid nodules, lungs, leflunomide
312
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947011
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946427
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946551
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945265
Most Viewed Current Articles
21 Jun 2024 : Case report
94,336
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
51,457
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
28,658
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,129
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030